Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

As of mid-May, this variant has been identified in nearly 11% of sequenced samples reported worldwide. The WHO has designated this variant as a “variant under monitoring,” and currently assesses the ...